fbpx
Size of letters 1x
Site color
Image
Additionally
Line height
Letter spacing
Font
Embedded items (videos, maps, etc.)
 

New procedure for clinical trials: EBA Clinical Trials Subcommittee discusses practical aspects of its implementation

12/ 06/ 2026
  The Clinical Trials Subcommittee of the European Business Association held an online meeting dedicated to the practical aspects of the new Procedure for the Conduct of Clinical Trials of Medicinal Products, approved by Order of the Ministry of Health of Ukraine No. 184. The new procedure has been developed as part of the implementation of Ukraine’s new Law “On Medicinal Products” and the transition to a new regulatory model in the field of medicinal product circulation. In line with the legislation, the launch of the single regulatory authority — the Ukrainian Pharmaceutical Agency — is scheduled for 1 January 2027. The Association has been actively involved in shaping this document and has consistently worked to improve it and align it with European regulatory approaches. In particular, the Clinical Trials Subcommittee contributed to its refinement both during the preparatory stage within a working group involving the Ministry of Health and the State Expert Centre, and throughout three rounds of public consultation, providing comments and proposals, a significant number of which were taken into account. During the meeting, participants discussed the key innovations of the new procedure, potential challenges for applicants/sponsors and the research community, as well as the practical application of certain provisions. Special attention was paid to provisions that may require further clarification. The speakers — representatives of Arzinger, the Subcommittee’s legal partner, Lana Sinichkina, Partner and Head of Healthcare and Pharmaceuticals Practice, and Kateryna Oliinyk, Partner of Intellectual Property and TMT Practice — provided expert explanations on the regulatory aspects of implementing the new requirements and shared their views on the future application of the relevant provisions. The European Business Association extends its gratitude to the experts from its legal partner Arzinger for their insightful presentations and practical clarifications, as well as to all participants for their active engagement and constructive discussion. The Clinical Trials Subcommittee of the Association will continue working on the issues discussed, including ongoing dialogue with regulatory authorities, to ensure the successful implementation of the new approaches in the field of clinical trials. We are convinced that open dialogue between the government and business is a key prerequisite for the effective implementation of new regulatory requirements and the further development of the clinical research sector in Ukraine.

The Clinical Trials Subcommittee of the European Business Association held an online meeting dedicated to the practical aspects of the new Procedure for the Conduct of Clinical Trials of Medicinal Products, approved by Order of the Ministry of Health of Ukraine No. 184.

The new procedure has been developed as part of the implementation of Ukraine’s new Law “On Medicinal Products” and the transition to a new regulatory model in the field of medicinal product circulation. In line with the legislation, the launch of the single regulatory authority — the Ukrainian Pharmaceutical Agency — is scheduled for 1 January 2027.

The Association has been actively involved in shaping this document and has consistently worked to improve it and align it with European regulatory approaches. In particular, the Clinical Trials Subcommittee contributed to its refinement both during the preparatory stage within a working group involving the Ministry of Health and the State Expert Centre, and throughout three rounds of public consultation, providing comments and proposals, a significant number of which were taken into account.

During the meeting, participants discussed the key innovations of the new procedure, potential challenges for applicants/sponsors and the research community, as well as the practical application of certain provisions. Special attention was paid to provisions that may require further clarification. The speakers — representatives of Arzinger, the Subcommittee’s legal partner, Lana Sinichkina, Partner and Head of Healthcare and Pharmaceuticals Practice, and Kateryna Oliinyk, Partner of Intellectual Property and TMT Practice — provided expert explanations on the regulatory aspects of implementing the new requirements and shared their views on the future application of the relevant provisions.

The European Business Association extends its gratitude to the experts from its legal partner Arzinger for their insightful presentations and practical clarifications, as well as to all participants for their active engagement and constructive discussion.

The Clinical Trials Subcommittee of the Association will continue working on the issues discussed, including ongoing dialogue with regulatory authorities, to ensure the successful implementation of the new approaches in the field of clinical trials. We are convinced that open dialogue between the government and business is a key prerequisite for the effective implementation of new regulatory requirements and the further development of the clinical research sector in Ukraine.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Start
in the Telegram bot
Read articles. Share in social networks
Nationwide Minute of Silence
01:00
09:00
Nationwide Minute of Silence
Let us honor the memory of all those who lost their lives in russia’s war against Ukraine
00:43

Spelling error report

The following text will be sent to our editors: